China-based Luye Pharma Group has entered into an agreement with South Korea's Myung In Pharm, granting the latter the exclusive rights to commercialise Rivastigmine Twice Weekly Transdermal Patch in South Korea. Developed by Luye Pharma, this drug is used to treat mild to moderate dementia associated with Alzheimer's disease (AD).